|Greg Guilcher, MD|
|Tony Truong, MD, MPH|
1 Canada site
1 to 19 Years
– Patients must be ≥ 12 months and < 19 years of age at the time of study enrollment. - Patients must have sickle cell disease as defined by hemoglobin electropheresis, as follows: - homozygous Hb S disease (HbSS), - sickle-Hb C disease (HbSC), - sickle beta-plus-thalassemia (HbS/β+), or - sickle beta-null-thalassemia (HbS/βo) - Patients must meet standard eligibility criteria to undergo HSCT, including but not limited to one or more of the following: - history of repeated (more than 1) bony (vaso-occlusive) crisis - history of stroke - elevated transcranial Doppler velocity not eligible for hydroxyurea, as per TWiTCH trial (ie. severe vasculopathy) - history of acute chest crisis or splenic sequestration crisis - history of priapism in males - history of osteonecrosis - pulmonary hypertension as documented by tricuspid regurgitation jet velocity (TRV) > 2.5 m/s on echocardiogram
– red cell allo-immunization (≥ 2 antibodies) during long term transfusion therapy
– Sickle complications should be present despite the use of hydroxyurea, but this is not
an absolute requirement, if the treating team considers the patient to be at high risk
for further crisis episodes.
– Patients who are unable to comply with or follow the study protocol.
– Patients with known hypersensitivity to sirolimus, its derivatives or to any of its